Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved]
The thrombotic microangiopathies (TMAs) are a group of diseases characterised by microangiopathic haemolysis, thrombocytopenia, and thrombus formation leading to tissue injury. Traditionally, TMAs have been classified as either thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2019-09-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/8-1690/v1 |
id |
doaj-cfc58556c17a412984d3295dc72d01e1 |
---|---|
record_format |
Article |
spelling |
doaj-cfc58556c17a412984d3295dc72d01e12020-11-25T03:18:50ZengF1000 Research LtdF1000Research2046-14022019-09-01810.12688/f1000research.19957.121904Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved]Neil S. Sheerin0Emily Glover1National Renal Complement Therapeutics Centre, Institute of Cellular Medicine, Newcastle University and Biomedical Research Centre, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle-upon-Tyne, UKNational Renal Complement Therapeutics Centre, Institute of Cellular Medicine, Newcastle University and Biomedical Research Centre, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle-upon-Tyne, UKThe thrombotic microangiopathies (TMAs) are a group of diseases characterised by microangiopathic haemolysis, thrombocytopenia, and thrombus formation leading to tissue injury. Traditionally, TMAs have been classified as either thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS) based on the clinical presentation, with neurological involvement predominating in the former and acute kidney injury in the latter. However, as our understanding of the pathogenesis of these conditions has increased, it has become clear that this is an over-simplification; there is significant overlap in the clinical presentation of TTP and HUS, there are different forms of HUS, and TMAs can occur in other, diverse clinical scenarios. This review will discuss recent developments in the diagnosis of HUS, focusing on the different forms of HUS and how to diagnose and manage these potentially life-threatening diseases.https://f1000research.com/articles/8-1690/v1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Neil S. Sheerin Emily Glover |
spellingShingle |
Neil S. Sheerin Emily Glover Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved] F1000Research |
author_facet |
Neil S. Sheerin Emily Glover |
author_sort |
Neil S. Sheerin |
title |
Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved] |
title_short |
Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved] |
title_full |
Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved] |
title_fullStr |
Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved] |
title_full_unstemmed |
Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved] |
title_sort |
haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2019-09-01 |
description |
The thrombotic microangiopathies (TMAs) are a group of diseases characterised by microangiopathic haemolysis, thrombocytopenia, and thrombus formation leading to tissue injury. Traditionally, TMAs have been classified as either thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS) based on the clinical presentation, with neurological involvement predominating in the former and acute kidney injury in the latter. However, as our understanding of the pathogenesis of these conditions has increased, it has become clear that this is an over-simplification; there is significant overlap in the clinical presentation of TTP and HUS, there are different forms of HUS, and TMAs can occur in other, diverse clinical scenarios. This review will discuss recent developments in the diagnosis of HUS, focusing on the different forms of HUS and how to diagnose and manage these potentially life-threatening diseases. |
url |
https://f1000research.com/articles/8-1690/v1 |
work_keys_str_mv |
AT neilssheerin haemolyticuremicsyndromediagnosisandmanagementversion1peerreview3approved AT emilyglover haemolyticuremicsyndromediagnosisandmanagementversion1peerreview3approved |
_version_ |
1724625631368445952 |